### Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 8-K

### ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/

Form 8-K August 07, 2003

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 5, 2003

# Arrhythmia Research Technology, Inc.

(Exact name of issuer as specified in its charter)

Delaware (State or other jurisdiction of Incorporation or organization) 1-9731 (Commission File Number) 72-0925679 (I.R.S. Employer Identification Number)

25 Sawyer Passway Fitchburg, MA 01420 (Address of principal executive offices and zip code)

#### (978) 345-5000

(Registrant s telephone number, including area code)

## Item 5. Other Events and Regulation FD Disclosures

On August 5, 2003 the Board of Directors of Arrhythmia Research Technology, Inc. (the Company) declared a cash dividend. The Company issued a press release dated August 5, 2003 announcing the cash dividend, which is attached as Exhibit 99.1 to this report.

## Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

(c). Exhibits

| Exhibit Number | <u>Description</u>  |
|----------------|---|
| 99.1           | Press Release dated August 5, 2003 announcing cash dividend.                                  |
| 99.2           | Press Release dated August 5, 2003 announcing its financial results for the 2nd quarter ended |
|                | June 30, 2003.  |

## **Item 12. Financial Statements**

On August 5, 2003, The Company issued a press release announcing its financial results for the 2<sup>nd</sup> quarter ended June 30, 2003. The press release is attached as Exhibit 99.2 to this report.

The information set forth in this Item 12 and Exhibit 99.2 are furnished to, but shall not be deemed filed with the Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise incorporated by reference into any filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such a filing.

### **SIGNATURE**

## Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fitchburg, Commonwealth of Massachusetts, on the 7<sup>th</sup> day of August 2003.

### ARRHYTHMIA RESEARCH TECHNOLOGY, INC.

By: <u>/s/ David A. Garrison</u>
David A. Garrison
Chief Financial Officer

### **Exhibit Index**

| Exhibit Number | <u>Description</u>  |
|----------------|---|
| 99.1           | Press Release dated August 5, 2003 announcing cash dividend.                                  |
| 99.2           | Press Release dated August 5, 2003 announcing its financial results for the 2nd quarter ended |
|                | June 30, 2003.  |

Exhibit Index 2